Tillotts Pharma AG
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
58%
7 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Role: lead
Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Role: lead
Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules
Role: lead
Mesalazine Treatment in IBS (The MIBS Study)
Role: collaborator
Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome
Role: collaborator
TP0502-B-Pharmaco-Scintigraphic-Study
Role: lead
TP0502-Pharmaco-Scintigraphic-Study and Amendment
Role: lead
TP0501 - Pharmaco-Scintigraphic-Study
Role: lead
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
Role: lead
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
Role: lead
EPANOVA in Crohn's Disease, Study 1
Role: lead
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Role: lead
All 12 trials loaded